The objective of this meta-analysis was to compare outcomes between sacubitril/valsartan
and enalapril in patients with heart failure. We performed this meta-analysis according to the …

Background: The effect of sacubitril/valsartan on survival and hospitalization risk in older
patients with heart failure has not been explored. We aimed to investigate the risk of …

This review aims to assess the benefits and adverse effects of sacubitril/valsartan in heart
failure, with a focus on important patient outcomes. A systematic review was conducted of …

We performed a meta-analysis investigating the efficacy and adverse effects of sacubitril–
valsartan in various types of heart failure including more recent studies and a larger sample …

Background: Sacubitril–valsartan has been shown to have superior effects over angiotensin-
converting enzyme inhibitors and angiotensin receptor blockers in patients with heart failure …

Background: To investigate the efficacy and safety of sacubitril-valsartan in patients with
heart failure, relevant randomized clinical trials (RCTs) were analyzed. Methods: We used …

Aims The efficacy and safety of sacubitril/valsartan for patients with heart failure with
preserved ejection fraction (HFpEF) are controversial. Hence, the primary objective of the …

Aims Sacubitril‐valsartan has been shown to have superior effects over angiotensin‐
converting enzyme inhibitors and angiotensin receptor blockers in patients with heart failure …

Current guidelines recommend angiotensin receptor blocker neprilysin inhibitors
(ARNI)(sacubitril/valsartan) as a replacement for angiotensin-converting-enzymeinhibitor …

Background: The PARADIGM HF trial showed sacubitril/valsartan (SV) to be superior to
enalapril in patients with reduced ejection fraction (HFrEF). Since its publication, several …